BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

...treat the same disease, Dobmeier said the therapies take different approaches. Atrasentan, an antagonist of endothelin receptor...
BioCentury | Jan 28, 2020
Clinical News

Acceleron readout supports sotatercept as disease-modifying option for PAH

...characterized by vasoconstriction caused by remodeling of pulmonary artery walls. The existing drugs -- prostacyclins, endothelin receptor...
BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

...from FDA indicating that additional data will be needed to evaluate an sNDA for the endothelin receptor...
BioCentury | Aug 22, 2019
Clinical News

After neurodegeneration miss, Retrophin looks to rebound with renal program

...is now turning its focus to renal candidate sparsentan. The small molecule dual angiotensin and endothelin receptor...
BioCentury | May 15, 2019
Finance

Sofinnova Investments-led syndicate forms CV play CinCor with $50M, Roche castoff

...clinic for treatment-resistant hypertension, with the most advanced being Phase III compound aprocitentan, a dual endothelin receptor...
BioCentury | Mar 22, 2019
Clinical News

Opsumit improves right ventricular function in PAH patients

...were presented at the American College of Cardiology meeting in New Orleans. Opsumit, a tissue-targeting endothelin receptor...
...adult patients of WHO functional class II-III. Brian Moy, Assistant Editor Opsumit, macitentan (act-064992, actelion-1) Actelion Ltd. Johnson & Johnson Endothelin receptor...
BioCentury | Feb 13, 2018
Distillery Therapeutics

Cancer

...MENAΔv6 was associated with high invasiveness. In a xenograft mouse model of ovarian cancer, the endothelin receptor...
BioCentury | Dec 8, 2017
Company News

J&J opts in for Idorsia's hypertension candidate

...Next year, Idorsia plans to start a Phase III trial of the orally active dual endothelin receptor...
...SIX:IDIA), Allschwil, Switzerland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cardiovascular Chris Lieu ACT-132577 Aprocitentan Idorsia Ltd. Johnson & Johnson Endothelin receptor...
BioCentury | Dec 4, 2017
Company News

J&J opts in for Idorsia's hypertension candidate

...Next year, Idorsia plans to start a Phase III trial of the orally active dual endothelin receptor...
...22 & June 16) . Idorsia remained unchanged at CHF21.55 on Monday. Chris Lieu ACT-132577 Aprocitentan Idorsia Ltd. Johnson & Johnson Endothelin receptor...
BioCentury | Jul 27, 2017
Product R&D

Spheres of influence

...thresholds employed. They also pointed to the spheroids’ ability to pick out cytotoxicity of the endothelin receptor...
Items per page:
1 - 10 of 416